If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

BIONi010-C-45

BIONi010-C iCRE AAVS1 GBA1 LoxP EX5-6

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Available within next 12 months
You will need to complete a Cell Line Information Pack (CLIP) before purchasing your cell line. Please contact us to receive the relevant document.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name BIONi010-C-45
Alternative name(s)
BIONi010-C iCRE AAVS1 GBA1 LoxP EX5-6
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)

Provider

Depositor Bioneer (BION)
Distributors
EBiSC

External Databases

hPSCreg BIONi010-C-45
BioSamples SAMEA6232065

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1

Characterisation#

No characterisation data could be found for this subclone. Please open parental cell line BIONi010-C .

Genotyping#

Karyotyping (Cell Line)

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
Gene knock-in
GBA1 gene, a LoxP site inserted in the intron before exon 5 and after exon 6
GBA1, A LoxP site inserted in the intron before exon 5 and after exon 6. After fluxing, by the induction of iCRE with doxycycline, a out-of-frame KO will be generated